[在瘤血液学和所谓的"天然"产品中进行的药学采访:用大麻 (CBD) 为例]
Lucas Fleta1, Pierre Valentin Laffitte1, Borhane Slama2
1Pharmacie à usage intérieur, centre hospitalier d'Avignon, Avignon, France.
Bulletin du cancer
|December 25, 2025
概括
在癌症患者中使用大麻素 (CBD) 可能会导致危险的药物相互作用. 药剂师在识别和预防这些相互作用方面发挥着关键作用,特别是在口服抗癌疗法中.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 药物相互作用 药物相互作用
背景情况:
- 随着口服疗法的使用增加,癌症治疗正在不断发展,需要新的患者支持系统.
- 患者越来越多地与传统治疗一起使用补充和替代药物.
- 药剂师是管理口服抗癌疗法的重要组成部分,专注于药物相互作用.
研究的目的:
- 突出口服抗癌疗法与草药相互作用的潜力.
- 为了强调与大麻 (CBD) 在癌症患者中使用相关的风险.
- 为了强调药剂师在预防药物不良事件中的作用.
主要方法:
- 关于大麻 (CBD) 代谢和药物相互作用潜力的文献综述.
- 对CBD对细胞染色体P450酶和药物载体的抑制作用的分析.
- 慢性髓性白血病 (CML) 治疗指南和药物基质的审查.
主要成果:
- 高剂量的CBD强烈抑制CYP3A4和P-gp;较低剂量也可能导致临床显著的抑制.
- 第一线CML治疗主要是CYP3A4基质,增加了与CBD相互作用的风险.
- 病例报告表明,即使在较低剂量的CBD中,也可能存在显著的草药相互作用.
结论:
- 在接受慢性髓性白血病 (CML) 治疗的患者中,由于显著的药物相互作用风险,强烈建议不使用大麻素 (CBD).
- 药剂师在多学科团队中至关重要,在开始口服抗癌治疗期间识别和管理潜在的相互作用.
- 草药相互作用的积极识别和管理对于瘤学中的患者安全至关重要.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
649
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
649
Drug Discovery: Overview
10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview
1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
Preclinical Development: Overview
5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Biopharmaceutics and Pharmacokinetics: Overview
3.2K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
3.2K
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K


